Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St Jude hits stented heart valve milestone:

This article was originally published in Clinica

Executive Summary

St Jude Medical says its has reached a significant milestone in its efforts to enter the US stented tissue heart valve market, after its Epic valve was implanted in the first patient of an FDA-approved clinical trial. The device, a porcine-based product, features the St Paul, Minnesota firm's proprietary Linx anti-calcification technology, designed to alleviate the calcification problems sometimes associated with tissue valves. Stented tissue valves represent around 45% of the current US heart valve market, says St Jude, which already markets the device, and another stented heart valve, called Biocor, outside the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel